The Italy Peptide Synthesis Market was valued at $17.6 Million in 2024 and projected to reach to $25.9 Million by 2029, representing a compound annual growth rate of 8.0%. Italy's peptide synthesis market is poised for steady expansion, driven by increasing investments in pharmaceutical R&D and the growing adoption of peptide-based therapeutics.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Italy's peptide synthesis market is valued at $17.6 million in 2024, with a projected CAGR of 8% through 2029, reaching $25.9 million by forecast end.
Italian pharmaceutical and biotech companies are increasingly outsourcing custom peptide manufacturing, driving demand for specialized synthesis services and contract research organizations.
Italy's strategic position within Europe's healthcare ecosystem enables access to EU regulatory frameworks, collaborative research networks, and cross-border pharmaceutical partnerships.
Italy's robust biotech sector, concentrated in regions like Lombardy and Lazio, supports peptide synthesis adoption for drug discovery, immunotherapy, and personalized medicine applications.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Has worked with GenScript Biotech Corporation (China) to generate thousands of peptides used to study T-cell receptor recognition and identify novel targets for solid-tumor therapeutics. | Enabled large-scale generation of diverse peptide libraries required for target discovery, supporting identification of tumor-specific targets and development of potentially safer and more effective T-cell receptor therapies. |
|
|
Uses Biotage AB (Sweden) peptide synthesis and downstream processing technologies, including Syro automated peptide synthesizers, Initiator+ microwave systems, Isolera purification systems, and V-10 evaporation systems, within its peptide drug-discovery workflows. | Parallel synthesis increased peptide throughput, while heated synthesis shortened coupling times for certain reactions from around one hour to about 10 minutes. The integrated workflow also supports difficult sequences, faster purification, and expansion of peptide discovery programs. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | CANCER (Indication) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 8.7% from 2024 to 2029 |
| Largest Segment | CHEMICAL METHODS (Technique) |
| Market Size Base Year (Billions) | ~USD 0.93 (2024) |
| Revenue Forecast (Billions) | ~USD 1.41 (2029) |
| Segments Covered | Offering, Type, Technique, Application, Indication |
5 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| FLUOR CORPORATION | United States | Public Company | Energy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining, infrastructure, staffing, maintenance),Mission Solutions (government nuclear, remediation, security, logistics, O&M), |
| MERCK KGAA | Germany | Public Company | Life Science (tools, consumables, CDMO, bioprocessing),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, gases, equipment), |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| GENSCRIPT | Hong Kong | Public Company | Life Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products, |
| BACHEM | Switzerland | Public Company | Peptide NCE APIs (clinical and commercial),Generic peptide APIs,Oligonucleotide NCE APIs, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery chemistry,Discovery biology and DMPK,Development services (chemical, formulation, analytical, clinical), |
| BIOTAGE | Sweden | Private Company | Flash chromatography systems and consumables,Sample preparation and SPE workflows,Biomolecule purification (antibody, plasmid, AAV, tagged proteins), |
| CEM CORPORATION | Mexico | Public Company | Gray ordinary Portland cement,White and blended cement, masonry products,Ready-mix concrete (standard and specialty), |
Fluor Corporation is a publicly traded engineering and construction company founded in 1912 and headquartered in the United States. With approximately 23,000 employees, the company provides design, engineering, procurement, and construction services across multiple industries.
Merck KGaA is a German publicly traded pharmaceutical, chemical, and life sciences company with roots dating back to 1668. The company employs approximately 59,000 people and operates globally across healthcare, life sciences, and performance materials sectors.
Agilent Technologies, Inc. is a publicly traded American company founded in 1999 that specializes in life sciences, diagnostics, and applied chemical markets. With approximately 18,000 employees, Agilent provides instruments, software, services, and consumables for laboratory and clinical settings.
GenScript is a Hong Kong-based publicly traded biotechnology company founded in 2002 with approximately 6,165 employees. The company provides gene synthesis, protein production, and drug discovery services to support research and development globally.
Bachem is a Swiss publicly traded company founded in 1971 with approximately 2,725 employees specializing in the production of biochemical compounds. The company serves the pharmaceutical, biotechnology, and diagnostics industries with custom synthesis and manufacturing services.
Syngene International Limited is an Indian publicly traded company founded in 1993 with approximately 6,692 employees providing integrated drug discovery and development services. The company offers preclinical, clinical, and manufacturing services to pharmaceutical and biotechnology clients worldwide.
Biotage is a Swedish private company founded in 1969 with approximately 622 employees specializing in laboratory chemistry and sample preparation solutions. The company develops and manufactures instruments and consumables for pharmaceutical, chemical, and environmental analysis.
CEM Corporation is a publicly traded company founded in 1906 and headquartered in Mexico with approximately 38,495 employees. The company operates across multiple industrial and commercial sectors providing manufacturing and related services.
Italy's peptide synthesis market was valued at $17.6 million in 2024 and is projected to reach $25.9 million by 2029.
Italy's peptide synthesis market is growing at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2029.
Italy's demand for peptide synthesis is driven by pharmaceutical research and development, custom manufacturing needs, and the country's established biotech sector.
Italy represents a significant segment of the European peptide synthesis market, benefiting from strong regulatory frameworks and proximity to major pharmaceutical hubs.
Italy's market offers opportunities in contract manufacturing services, research infrastructure expansion, and therapeutic peptide development through 2029.
This research study relied extensively on secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global peptide synthesis market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives at major market players, and industry consultants, to gather and validate critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the peptide synthesis market. The secondary sources used for this study include US Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institutes of Health (NIH), European Directorate for the Quality of Medicines & HealthCare (EDQM), Japan Pharmaceuticals and Medical Devices Agency (PMDA), World Health Organization (WHO), US Pharmacopeia (USP), ClinicalTrials.gov, Journal of Peptide Science, International Journal of Peptide Research and Therapeutics, Peptide Science, American Peptide Society (APS), European Peptide Society (EPS), Chemical & Engineering News (C&EN), Genetic Engineering & Biotechnology News (GEN), and BioPharm International; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations, among others. These sources were also used to obtain key information on major players, market classification and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess the market's future prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the peptide synthesis market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following.

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Peptide synthesis is the process of producing peptides through the controlled assembly of amino acids into specific sequences using chemical, biological, or hybrid manufacturing approaches.
The peptide synthesis market comprises the global commercial market for products and services used to chemically or biologically synthesize, modify, purify, and characterize peptides for research, drug discovery and development, diagnostics, therapeutics, and other life science applications. The market includes peptide synthesis instruments and systems, synthesis reagents and building blocks, purification and analytical instruments, synthesis-related consumables, and custom peptide synthesis services. Services covered include custom peptide synthesis, peptide engineering and modification, peptide labeling and conjugation, peptide purification, and peptide-specific analytical and characterization services provided by CROs, CDMOs and specialized peptide service providers.
Based on the given market data, MarketsandMarkets offers customization to meet the company’s specific needs. The following customization options are available for this report:
Detailed analysis and profiling of additional market players (up to five).
Full forecast, segment splits, and company analysis for all Peptide Synthesis Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report